← Back to Search

Cancer Vaccine

HIV Vaccines for HIV (CM HIV-Core008 Trial)

Phase 1
Waitlist Available
Led By Cindy L Gay, MD, MPH
Research Sponsored by University of North Carolina, Chapel Hill
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first day of study treatment through day 196 (20 weeks following second vaccination), an average of 7 months

Summary

This trial is testing two vaccines given as muscle injections to people with HIV who are already on treatment. The goal is to see if these vaccines are safe and if they can help the immune system better fight the virus. Participants will receive the injections and be monitored for any reactions.

Who is the study for?
This trial is for adults aged 18-70 with HIV, on stable ART with undetectable viral load and CD4 count >=350. They must be willing to follow the study plan, have no recent serious illness or hospitalization, not pregnant or planning pregnancy, and agree to use birth control. Excluded are those with certain medical conditions, prior adenovirus vaccines including COVID-19 ones, live vaccines within 60 days, untreated syphilis or HCV treatment recently.
What is being tested?
The trial tests if C62-M4 or C1C62-M3M4 vaccines are safe in HIV-positive individuals on ART and whether they boost immune responses against HIV. Participants will receive intramuscular injections of either vaccine formulation or a placebo and their T cell responses will be monitored.
What are the potential side effects?
Potential side effects may include typical vaccine reactions like soreness at injection site, mild fever, fatigue; allergic reactions; possible impact on underlying condition due to immune response changes. Specific risks related to these experimental vaccines will be closely monitored.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first day of study treatment through day 196 (20 weeks following second vaccination), an average of 7 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and first day of study treatment through day 196 (20 weeks following second vaccination), an average of 7 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percent of Participants With a Grade 3 or Higher Treatment-Related Adverse Event (AE)
Secondary study objectives
Body Weight Changes
Percent of Participants With a Grade 1 or Higher Treatment-Related Adverse Event (AE)
Relative change in magnitude of T cell responses to HIV-1 conserved regions

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: C62Experimental Treatment2 Interventions
C62 administered at Day 0 and M4 on Day 28
Group II: C1C62Experimental Treatment2 Interventions
C1C62 administered at Day 0 and M3M4 on Day 28
Group III: PlaceboPlacebo Group1 Intervention
Placebo administered on Day 0 and Day 28

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
HIV vaccines like C62-M4 or C1C62-M3M4 work by targeting conserved regions of the HIV-1 virus to enhance HIV-1-specific T cell responses. These vaccines aim to improve the body's ability to recognize and attack HIV-infected cells, which is crucial for controlling the virus, reducing viral load, and delaying disease progression. By focusing on stable viral regions, these vaccines provide a more consistent target for the immune system, potentially leading to better long-term outcomes for patients.
Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides.

Find a Location

Who is running the clinical trial?

University of North Carolina, Chapel HillLead Sponsor
1,569 Previous Clinical Trials
4,319,689 Total Patients Enrolled
National Institute of Allergy and Infectious Diseases (NIAID)NIH
3,336 Previous Clinical Trials
5,392,816 Total Patients Enrolled
1 Trials studying HIV Vaccine
20 Patients Enrolled for HIV Vaccine
Cindy L Gay, MD, MPHPrincipal InvestigatorUniversity of North Carolina
2 Previous Clinical Trials
41 Total Patients Enrolled
Nilu Goonetilleke, PhDPrincipal InvestigatorUniversity of North Carolina
1 Previous Clinical Trials
26 Total Patients Enrolled

Media Library

C1C62-M3M4 (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT05604209 — Phase 1
HIV Vaccine Research Study Groups: C1C62, C62, Placebo
HIV Vaccine Clinical Trial 2023: C1C62-M3M4 Highlights & Side Effects. Trial Name: NCT05604209 — Phase 1
C1C62-M3M4 (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05604209 — Phase 1
~6 spots leftby Dec 2025